- First patient treated in new heavy‑chain‑only antibody trial
- Novo Nordisk and AWS form AI partnership to speed drug discovery
- Kupando doses first patient in phase 1 trial
- First-in-class house dust mite allergy treatment now available in Scotland
- NHS backs new treatment option for cystinosis
- Fridge‑free vaccine shows global potential
- Lexeo wins FDA RMAT status for LX2020
- EHP Awards 2027 open for entries
- NICE backs new blood cancer regimens
- Obsidian begins registration cohort for amsoki-cel
- Entera Bio data selected for ASBMR plenary session
- NHS backs delayed‑release treatment for cystinosis
- Oblenio doses first patients in phase 1a autoimmune trial
- BeOne Medicines secures UK innovation passport for HCC therapy
- Sanofi’s MenQuadfi approved for EU infants
- Qnovia licenses novel antimicrobial peptide
- Lexeo wins FDA RMAT status for LX2020
- Polpharma Biologics gains FDA and EMA review acceptances
- Parsortix study shows promise for ADC target detection
- Vista trial begins dosing in precision cancer vaccine study
Website: https://www.pharmatimes.com
